These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 11025776)

  • 1. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
    Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
    J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
    Nam RK; Reeves JR; Toi A; Dulude H; Trachtenberg J; Emami M; Daigneault L; Panchal C; Sugar L; Jewett MA; Narod SA
    J Urol; 2006 Apr; 175(4):1291-7. PubMed ID: 16515983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
    Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
    J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
    Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
    Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
    Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
    Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
    Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
    Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
    Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.
    Reeves JR; Dulude H; Panchal C; Daigneault L; Ramnani DM
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6018-22. PubMed ID: 17062675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z; Wenlu S
    Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models.
    Huizen IV; Wu G; Moussa M; Chin JL; Fenster A; Lacefield JC; Sakai H; Greenberg NM; Xuan JW
    Clin Cancer Res; 2005 Nov; 11(21):7911-9. PubMed ID: 16278416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
    Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
    J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of serum prostate specific antigen and quantitative immunohistochemistry.
    Weir EG; Partin AW; Epstein JI
    J Urol; 2000 Jun; 163(6):1739-42. PubMed ID: 10799172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer.
    Girvan AR; Chang P; van Huizen I; Moussa M; Xuan JW; Stitt L; Chin JL; Yamasaki Y; Izawa JI
    Urology; 2005 Apr; 65(4):719-23. PubMed ID: 15833515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
    Zhigang Z; Wenlu S
    Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.